Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights
August 05, 2020 16:01 ET
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020Flexion resumed enrollment in Phase 1 dose-escalation trial...
Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020
July 30, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its second-quarter 2020 financial results and recent business...
Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales
July 14, 2020 06:59 ET
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA (triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarterDemand for ZILRETTA from healthcare providers...
Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020 16:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., June 16, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in...
Flexion Therapeutics Announces Pricing of Public Offering of Common Stock
May 21, 2020 07:30 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at...
Flexion Therapeutics Announces Proposed Public Offering of Common Stock
May 20, 2020 16:01 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has commenced an underwritten public offering of $75,000,000 of shares of its...
Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference
May 13, 2020 17:00 ET
|
Flexion Therapeutics, Inc.
BURLINGTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an...
Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights
May 07, 2020 16:01 ET
|
Flexion Therapeutics, Inc.
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $20.1 million in first quarter 2020Flexion implementing broad cost savings initiatives; guiding...
Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting
May 05, 2020 09:00 ET
|
Flexion Therapeutics, Inc.
FX201 preclinical in vivo data in a rodent model of OA showed slowing of disease progression 12 weeks post-surgery, persistence of the vector genome in the joint for at least 92 days with absence of...
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
May 01, 2020 09:00 ET
|
Flexion Therapeutics, Inc.
An analysis of prospective radiographic assessments of 305 patients showed no adverse joint effects following treatment with ZILRETTA®Analysis of patient mobility indicated patients treated with...